发明名称 COMPOSITIONS AND METHODS FOR BONE FORMATION AND REMODELING
摘要 The mechanism by which the high bone mass (HBM) mutation (G171 V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein- mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a praracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autorcine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an incrase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.
申请公布号 CA2771951(C) 申请公布日期 2014.07.08
申请号 CA20052771951 申请日期 2005.05.18
申请人 ENZO THERAPEUTICS, INC. 发明人 ZHANG, YAZHOU;LIU, PENG;LI, XIAOFENG;ZHANG, JIE;SHAN, JUFANG;ENGELHARDT, DEAN;WU, DIANQING
分类号 A61K31/538;A61K9/68;A61K31/185;A61K31/4709;A61P19/08;C40B30/02;G01N33/48;G01N33/50;G01N33/53;G01N33/68;G06F19/00 主分类号 A61K31/538
代理机构 代理人
主权项
地址